Phase 3 Trial Enrollment Underway for Parkinson’s Disease Motor Movement Therapy
NeuroDerm has started enrolling Parkinson’s disease (PD) patients in iNDiGO, a Phase 3 clinical trial evaluating the effectiveness of ND0612L, the company’s levodopa/carbidopa (LD/CD) subcutaneous liquid formulation. Levodopa and dopamine agonists, the first line of defense against Parkinson’s disease, are drugs commonly used to improve and control the symptoms of tremor, muscular…